Recorded: 08 May 2008
We were looking for data out there that we could use and we could apply [to] our systems. And what we did is we used a lot of public databases that had clinical variation information in there. And over the last three, four years, funded by NIH [National Institutes of Health], we developed our systems. So the idea was if you take a sequence file, you just run it through our system, and out comes a full profile of any kind of clinical information for that individual. So again we linked medical data from literature to a genomic sequence. And it was very exciting when so quickly last year, we got a real data set like Jim’s to do this. And it was interesting to see because we have no idea, what does it actually mean if we have a complete sequence? That was exciting. People have done individual genetic traits, individual genes. But in our instance, we had the whole genome. And it was very exciting to see how that would look, you know, clinically from a relevant whole genome. And a good test case, of course.
Martin Reese is the Co-founder, Chief Executive Officer, and Chairman of the Board of Omicia.
Dr. Martin Reese is an internationally recognized expert in medical informatics and bioinformatics with a track record of bringing strong, grounded scientific knowledge to the corporate sector. Prior to founding Omicia, Dr. Reese served as Vice President of Discovery Informatics for ValiGen. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project. This project provided the essential proof-of-concept platform for Celera's famous shotgun sequencing technology, which is now internationally recognized - as driving a new standard of excellence in sequencing. It was while at the Lawrence Berkeley National Laboratories that Dr. Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of California, Berkeley and the University of Hohenheim, Germany.